BALA CYNWYD, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage…
Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 Company management…
With current cash and projected revenue, offering is expected to fund operations to profitabilityCAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE)…
Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their AAV programs Bedford, Massachusetts –…
SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases Proceeds to fund…
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models…
MEMPHIS, Tenn., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Black mothers die in hospitals at nearly four times the rate of White mothers…
Clinical Leadership and Management Call to FollowSunnyvale, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of…
BOCA RATON, Fla., Sept. 14, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the…
NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…